Paramasivan C N, Venkataraman P
Tuberculosis Research Centre (ICMR), Mayor V.R. Ramanathan Road, Chetput, Chennai 600-031, India.
Indian J Med Res. 2004 Oct;120(4):377-86.
The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs viz., isoniazid and rifampicin. The level of initial drug resistance is an epidemiological indicator to assess the success of the TB control programme. Though drug resistance in TB has frequently been reported from India, most of the available information is localized, sketchy or incomplete. A review of the few authentic reports indicates that there is no clear evidence of an increase in the prevalence of initial resistance over the years. However, a much higher prevalence of acquired resistance has been reported from several regions, though based on smaller numbers of patients. A strong TB control programme and continuous surveillance studies employing standardized methodology and rigorous quality control measures will serve as useful parameters in the evaluation of current treatment policies as well as the management of multidrug resistant (MDR) TB cases.
当前全球在结核病治疗方面的关注点是对两种最有效的药物——异烟肼和利福平产生耐药性。初始耐药水平是评估结核病控制项目成效的一项流行病学指标。尽管印度经常报告结核病耐药情况，但大多数现有信息都是局部的、粗略的或不完整的。对少数可靠报告的综述表明，没有明确证据显示多年来初始耐药率有所上升。然而，尽管基于的患者数量较少，但几个地区报告的获得性耐药率要高得多。一个强有力的结核病控制项目以及采用标准化方法和严格质量控制措施的持续监测研究，将成为评估当前治疗政策以及耐多药结核病病例管理的有用参数。
